08/01/2019 12:00:00

CureVac Announces U.S. Patent Grant for mRNA Vaccination of Infants Against RSV

Important New Patent to Allow CureVac to Develop Vaccine Candidate for Neglected Respiratory Condition

TÜBINGEN, Germany and BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, announced that the U.S. Patent and Trademark Office (USPTO) has granted a fundamental patent for the use of mRNA encoding the Respiratory Syncytial Virus (RSV) F-protein for vaccination of infants up to two years of age (US Patent No. 10,172,935). The F-protein is the major antigen of RSV and forms the basis of potential future RSV vaccines. The USPTO already granted a similar patent in 2017 that relates to vaccination of infants for the prophylaxis of influenza. Moreover, similar patents have already been granted to CureVac in Europe and Japan. Together, these broad technology patents strengthen CureVac’s industry-leading position in the mRNA space as the Company develops preventative vaccine candidates for severe infectious diseases, such as RSV and influenza.

CureVac’s mRNA technology uses optimized mRNA encoding F-protein to stimulate a protective and balanced immune response against RSV. For such optimized mRNA constructs, CureVac already holds a U.S. patent that supplements CureVac’s patent portfolio regarding RSV vaccination.

Vaccination of infants is especially difficult because they do not yet have fully established immune systems. Several efforts in the industry to develop and market a prophylactic RSV vaccine have failed to date. Therefore, vaccination of infants against RSV remains an unmet need and one of the major challenges for prophylactic vaccination.

This patent strengthens CureVac’s broad IP portfolio, among the most comprehensive in the industry, with more than 110 patent families, over 1000 patent family members and more than 190 granted patents.

About RSV

RSV is a common respiratory virus and is the most common cause of bronchiolitis and pneumonia in children younger than one year of age in the U.S. An estimated 3.4 million children younger than five years of age are hospitalized each year with severe RSV lower respiratory tract infection, with the highest incidence in children younger than six months of age. RSV is second only to influenza as a cause of medically significant respiratory tract illnesses in adults and is estimated to cause 177,000 hospitalizations and 14,000 annual deaths in U.S. adults age 65 years and older. In the northern hemisphere and areas with similar climates, RSV infections occur primarily during fall, winter, and spring.1

About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, prophylactic vaccines and molecular therapies.

To date, CureVac has received approximately $420 million (€400 million) in equity investments including significant investments from SAP founder Dietmar Hopp’s Dievini and an investment of $52 million from the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, Arcturus Therapeutics, Acuitas, and the Bill & Melinda Gates Foundation.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.

Media Contact

Jenn Gordon, Media Relations

Global Health PR, New York, United States

T: +1 202-587-2580

jgordon@globalhealthpr.com

Investor Contact

Matthew Beck, Vice President Investor Relations

CureVac AG, Boston, MA, United States

T: +1 917-415-1750

matthew.beck@curevac.com

1 “Respiratory Syncytial Virus Infection” Centers for Disease Control and Prevention. June 2018. Last Accessed January 2019. https://www.cdc.gov/rsv/index.html

CureVac Logo mit Claim RGB.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
19 Mar
I:SP500
Hejsa Lidt forårs opdatering. Langsigtet konjunkturmodel: Nederst kan I se den langsigtede konjunktu..
70
19 Mar
VELO
  Studiet er et randomiseret fase 4 forsøg, hvor man sammenligner forlænget frigivelse Envarsus XR (..
14
18 Mar
GOMX
SAS's emmision overtegnet så de regner med 15MUSD i provenu samlet - godt nyt for GOMSpace hvis de k..
14
21 Mar
BAVA
Jeg synes bestemt også der skal være plads til kritikere af Bavarian. Der skal være plads til alle i..
12
20 Mar
ZEAL
Jeg skrev til IR vedr. lidt forskelligt, her er deres svar:  Bliver der afholdt en Capital Market D..
12
21 Mar
PNDORA
Du rammer jo netop ned i strategien "NOW", hvor der kigges ind i hvilke butikker der er lønsomme. Sa..
11
19 Mar
FING-B
Siden topformationen i 23 området har trenden krydset flere støttelinjer og er nu ved en mulig dobbe..
11
18 Mar
BAVA
For mig virker det ret underligt at udmelding fra FDA om ydereligere 3mdr mere behandlingstid bliver..
11
21 Mar
I:SP500
Der er en alt afgørende ting som Rangvid ikke tager højde for, og som Lars Christensen glemmer at kr..
10
17 Mar
CHEMM
Økonomisk Ugebrev Formue har i denne weekend et længere interview med Chemometecs CEO Michael Eising..
10

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FSIS Recall Release 034-2019 Foreign Matter Contamination
2
Huanyu Entertainment, Producer of Story of Yanxi Palace, Participated in HK FILMART 2019 With Two New Productions Focusing on Chinese Traditions
3
GOGL - Filing of 2018 Annual Report on Form 20-F
4
Granite Oil Corp. Reports Year End 2018 Financial Results
5
ALTA MESA SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Alta Mesa Resources, Inc. f/k/a Silver Run Acquisition Corporation II - AMR

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 March 2019 19:08:52
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190320.1 - EUROWEB7 - 2019-03-22 20:08:52 - 2019-03-22 19:08:52 - 1000 - Website: OKAY